Continence Reports最新文献

{"title":"Eccentric cases of genitourinary fistula—Our ten years of experience","authors":"Sakineh Hajebrahimi ,&nbsp;Elham Jahantabi ,&nbsp;Ehsan Sepehran ,&nbsp;Sherif Mourad ,&nbsp;Hanieh Salehi-Pourmehr","doi":"10.1016/j.contre.2023.100026","DOIUrl":"https://doi.org/10.1016/j.contre.2023.100026","url":null,"abstract":"<div><h3>Background:</h3><p>A fistula is an unusual connection between two organs, vessels, or structures. Urological fistulas in developed countries are consequences of iatrogenic injury, and the more common cause of fistula development in these countries is related to labor sequence.</p></div><div><h3>Case presentation:</h3><p>More than 156 cases were treated in our hospitals during the last 10 years, and in this case report, we present only unusual fistula from two different urology departments. Different cases with a variety of fistula including huge stone formation following vesicouterine fistula, vesicosacral fistula and expelling urine from bedsore region of sacrum, fistula in the junction of the orthotopic neobladder, and fistula in a patient with duplicated collecting system are presented in the current study.</p></div><div><h3>Conclusion:</h3><p>Vesicouterine fistula after cesarean section (C/S) led to the formation of a huge intrauterine stone. Vesicouterine fistula is the least common form of fistula, and C/S is the most common cause of this type of fistula. However, this type of fistula is not always associated with urinary incontinence due to the cervix’s sphincter-like mechanism. Vesicocutaneous fistula is another uncommon type. Iatrogenic injury, extensive trauma, irradiation of malignancies, and various other etiologies, can lead to Vesicocutaneous fistula. For these cases, both conservative, and surgery can be considered. However, surgery is the only definitive repair method. Moreover, fistula in the junction of orthotopic neobladder to the vagina, and left ureter to vagina fistula in a patient with duplicated collecting system are among the strangest urogynecological fistulas.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"6 ","pages":"Article 100026"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49715438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial urinary sphincters in males and females and neurogenic patients, techniques, and indications","authors":"Ghazal Ameli ,&nbsp;Emmanuel Jean Chartier-Kastler ,&nbsp;Ralf G. Anding ,&nbsp;Frank Van der Aa ,&nbsp;Craig V. Comiter ,&nbsp;Wilhelm A. Hübner","doi":"10.1016/j.contre.2023.100028","DOIUrl":"https://doi.org/10.1016/j.contre.2023.100028","url":null,"abstract":"<div><p>The introduction of the artificial urinary sphincter (AUS) in 1972 was heralded as a revolution for the treatment of stress incontinence (Scott et al., 1973). The evolution of the AUS has affected the current surgical options for urinary incontinence. With its unique features, the AUS has been an attractive option for the treatment of urinary incontinence regardless of gender. The device has evolved in the last decades and has now been in routine clinical use for nearly 50 years (Burkhard et al., 2019). Furthermore, the indications and surgical principles involved in its use along with short- and long-term outcomes are more clearly defined. The main indications for AUS insertion are post-prostatectomy incontinence (PPI), sphincter weakness incontinence due to neurogenic bladder dysfunction, intrinsic sphincter deficiency (ISD) and rare congenital causes of incontinence. In the following we summarize the conclusions worked out during the expert workshop on artificial urinary sphincter during ICS 2022 in Vienna, Austria; and present some strategies for difficult cases.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"6 ","pages":"Article 100028"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49732509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leaking all the time and for no obvious reason are clinical markers of incontinence severity: A cross-sectional study","authors":"José Miguel Gómez de Vicente ,&nbsp;Luis López-Fando ,&nbsp;Luis Martínez-Piñeiro","doi":"10.1016/j.contre.2023.100029","DOIUrl":"https://doi.org/10.1016/j.contre.2023.100029","url":null,"abstract":"<div><h3>Introduction:</h3><p>Leaking for no obvious reason and leaking all the time are unusual urinary incontinence patterns. They are often associated to most severe incontinence cases. However, its real impact in severity and impact on quality of life has not been extensively studied</p></div><div><h3>Objective:</h3><p>To determine the influence on severity and impact on quality of life of these two types of urinary leakage in patients with stress, urgency or mixed UI based on ICIQ-UI questionnaire.</p></div><div><h3>Study design:</h3><p>We performed a retrospective analysis of the ICIQ-UI questionnaire in 560 non-neurogenic patients complaining of UI. Patients were classified according to their UI pattern into stress, urgency or mixed UI. Frequency (Q1: 0-5), amount (Q2: 0-6), impact in quality of life (Q3: 0-10) as well as total ICIQ-UI scores were compared between patients who claimed to also have leakage for no obvious reason (LforNOR) or all the time (LAT) and those who did not. UI patterns were stratified according to its severity.</p></div><div><h3>Results:</h3><p>203 males and 357 females were studied. Scores for frequency, amount, impact on quality of life and total ICIQ-UI scores were significantly higher for women who LAT (4.7 vs 3.3, 5.4 vs 3.4, 9.3 vs 6.8 and 19.4 vs 13.4 respectively, all with p&lt;0.001) or LforNOR (4.1 vs 3.4, 4.5 vs 3.5, 8.6 vs 6.7 and 17.1 vs 13.6, all with p&lt;0.001). In men, mean Q1, Q2, Q3 and total ICIQ-UI scores were also higher in those with LAT (4.6 vs 2.9, 5 vs 2.8, 9.1 vs 5.3 and 18.7 vs 11 respectively, all with p&lt;0.001) and LforNOR (3.9 vs 2.8, 4.2 vs 2.7, 7.6 vs 5.2 and 15.6 vs 10.7 all with p&lt;0.001). ICIQ-UI scores were also significantly higher when controlling for UI pattern with or without LforNOR or LAT. Stratification of incontinence severity by UI patterns with or without these two types of leakage had clinical consistency as most patients with LforNOR and LAT had higher ICIQ-UI scores.</p></div><div><h3>Conclusion:</h3><p>Leaking for no obvious reason and leaking all the time are clinical markers of incontinence severity.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"6 ","pages":"Article 100029"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49734723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid-term performance of laparoscopic sacrocolpopexy using polytetrafluoroethylene mesh ORIHIME®","authors":"Masami Takeyama,&nbsp;Masaki Watanabe,&nbsp;Tomoko Kuwata,&nbsp;Hiromi Kashihara,&nbsp;Chikako Kato","doi":"10.1016/j.contre.2023.100022","DOIUrl":"https://doi.org/10.1016/j.contre.2023.100022","url":null,"abstract":"<div><p>Since 2017, polytetrafluoroethylene (PTFE) mesh ORIHIME® has been available in Japan for pelvic organ prolapse surgery. PTFE mesh is a potential material for the reconstruction of pelvic floor, however, there have not been any report on the LSC using PTFE mesh. The aim of the study is to confirm the feasibility of LSC with PTFE mesh by investigating the mid-term outcomes of LSC with this mesh. The materials were ORIHIME® and 30 patients with POP who underwent LSC using ORIHIME® in 2018. All cases underwent double mesh LSC, and subtotal hysterectomy was carried out concomitantly. Mean operation time was 145 min. We experienced no intraoperative complication. The patients were to be followed up to 3 years after operation. But only 19 patients were able to be followed up to 3 years. We experienced no mesh related complication. Stress urinary incontinence was seen in 8 patients (27%). As for recurrence of POP, we saw 3 cases (10%). Considering the results, LSC with PTFE mesh may have potential in reconstructing the female pelvic floor of POP patients.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"5 ","pages":"Article 100022"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49713545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does acupuncture improve overactive bladder symptoms? A protocol for a qualitative study to explore patient experiences of receiving acupuncture for OAB symptoms","authors":"Emma Hargreaves ,&nbsp;Jenni Naisby ,&nbsp;Gill Barry ,&nbsp;Katherine Baker","doi":"10.1016/j.contre.2023.100023","DOIUrl":"https://doi.org/10.1016/j.contre.2023.100023","url":null,"abstract":"<div><p>Overactive bladder (OAB) affects around 12% of the adult population and is the subject of thousands of studies. Qualitative studies of OAB are less common and the patient voice is rarely heard. This protocol outlines the theoretical framework underpinning the study and defines the methodology that will be used to investigate the lived experience of OAB and choices regarding treatment options. This study will reference the patient experience of receiving acupuncture for OAB symptoms, a novel treatment with a growing evidence base. This is the first study to address patient experience related to acupuncture for OAB and may produce information of use to people with OAB, clinicians and those developing new pathways of care.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"5 ","pages":"Article 100023"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49713548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost, resource utilization, and treatment-taking behaviors among patients with OAB initiating combination mirabegron and antimuscarinic therapy in the US","authors":"Stephen R. Kraus ,&nbsp;Amy Lockefeer ,&nbsp;Greta Lozano-Ortega ,&nbsp;Baoguo Jiang ,&nbsp;Tomomi Kimura ,&nbsp;Basia Rogula ,&nbsp;Sally Miller ,&nbsp;David Walker","doi":"10.1016/j.contre.2022.100020","DOIUrl":"https://doi.org/10.1016/j.contre.2022.100020","url":null,"abstract":"<div><h3>Aims:</h3><p>To estimate costs, number of encounters, and adherence and persistence, among overactive bladder (OAB) patients initiating mirabegron (MIRA) and antimuscarinic (AM) combination therapy.</p></div><div><h3>Methods:</h3><p>In this retrospective cohort study using US claims data, incident combination therapy users (identification period: April 2018–March 2019) were followed for one year from first observed combination therapy fill (index) and stratified into four treatment pathways based on subsequent treatments used: continued combination therapy, switched to monotherapy, discontinued combination therapy or transitioned to OAB procedures (e.g., onabotulinumtoxinA injection). Outcomes were all-cause and OAB-related healthcare per-patient-per-month (PPPM) costs, number of encounters, treatment persistence and adherence. The cohort was weighted to align with the age distribution of the population of interest.</p></div><div><h3>Results:</h3><p>Patients (n=761) were 69% female; mean age was 67.8 years. Median (interquartile range [IQR]) all-cause PPPM costs ranged from $1,432 ($785, $2,914) for the combination therapy group to $2,335 ($1,482, $5,152) for the procedures group. OAB-related costs were lowest for the discontinuers ($362 [$222, $522]) and highest for those receiving procedures ($810; [$512, $1,433]). The median (IQR) PPPM number of OAB-related outpatient services encounters was 0.2 (0.1, 0.3; similar across treatment pathway groups). Treatment persistence was 167 (83, 300) days; adherence through day 365 was 26%.</p></div><div><h3>Conclusions:</h3><p>Monthly all-cause healthcare costs were similar among all patients except for those that transitioned to receive an OAB procedure, which was associated with higher costs. Persistence on combination therapy was similar to published persistence estimates for MIRA monotherapy and was potentially higher than published reports of AM persistence, though adherence may be lower.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"5 ","pages":"Article 100020"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49713542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can recurrent UTIs in women be cured? Review article","authors":"Valeerat Swatesutipun","doi":"10.1016/j.contre.2023.100021","DOIUrl":"https://doi.org/10.1016/j.contre.2023.100021","url":null,"abstract":"<div><p>Uncomplicated urinary tract infection (UTI) is common, resulting in a wide range of expenses and disturbing quality of life, especially in women.</p><p>Clinicians should take patients’ complete history and physical examination to determine the cause of recurrent UTI, and should consider further investigation in patients who are suspected of having complicated UTI. A urine culture is mandatory for recurrent UTI in every episode of symptomatic infection, before starting treatment. The antibiotic can be nitrofurantoin, TMP-SFX, or fosfomycin, for no longer than 7 days, to treat episodic uncomplicated infection patients. Post-coital prophylaxis show efficacy for recurrent UTI associated with sexual activity in premenopausal women. Non-antibiotic prophylaxis and low dose antibiotic prophylaxis can be used for patients who have frequent recurrent UTIs. Vaginal estrogen has efficacy to treat recurrent UTIs for post-menopausal women. Good hygiene is generally advised, despite limited data to support it. The vaccine for recurrent cystitis has opened a new door for the treatment of women with recurrent cystitis, however, long tern data are needed to confirm the efficacy.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"5 ","pages":"Article 100021"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49729466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19-associated Guillain–Barrè Syndrome and Urinary Dysfunction: A case report","authors":"Marilena Gubbiotti ,&nbsp;Wally Mahfouz ,&nbsp;Anastasios D. Asimakopoulos ,&nbsp;Ludovica Durante ,&nbsp;Giacomo Maria Pirola ,&nbsp;Daniele Castellani ,&nbsp;Emanuele Rubilotta","doi":"10.1016/j.contre.2022.100017","DOIUrl":"10.1016/j.contre.2022.100017","url":null,"abstract":"<div><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection can cause multiple systemic and neurological complications, including Guillain–Barrè Syndrome (GBS). In this report we describe for the first time, urinary dysfunction in a patient with COVID-19. We reported a 41-years-old female patient with complaints of an increased generalized muscular weakness associated with progressive difficulty in walking. Four days earlier, patient complained of fever, diarrhea, and general weakness, and the RT-PCR was positive for COVID-19 infection. Due to the worsening of neurological symptoms, a neurophysiological examination on nervous conduction was performed and the diagnosis was suggestive of GBS. Two weeks later, patient developed two consecutive episodes of acute urinary retention that requested the placement of indwelling transurethral catheter. Patient started assuming selective alpha-1 adrenergic antagonist in association with 4 clean intermittent catheterization/die. Four months later, women continued the therapy and the ultrasound evaluation revealed non-pathologic post-void residual volume. Therefore, patient started to void spontaneously again and alpha-blockers were discontinued. We report for the first time a case of severe voiding disorder in a patient with COVID-19 associated GBS. Timely bladder drainage should be adopted to avoid irreversible detrusor damage.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"4 ","pages":"Article 100017"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772974522000114/pdfft?md5=40e2bb0d914d7753915c1c5edbf6bb2d&pid=1-s2.0-S2772974522000114-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80687974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A shared B-cell clonotype in patients with Interstitial Cystitis/Bladder Pain Syndrome presenting with Hunner lesions","authors":"Inna Tabansky ,&nbsp;Robert M. Moldwin ,&nbsp;Min Liu ,&nbsp;Souhel Najjar ,&nbsp;Derin B. Keskin ,&nbsp;Vishaan Nursey ,&nbsp;Micheline Laurent ,&nbsp;Lori A. Birder ,&nbsp;Vladimir Brusic ,&nbsp;Guanglan Zhang ,&nbsp;Joel N.H. Stern","doi":"10.1016/j.contre.2022.100015","DOIUrl":"10.1016/j.contre.2022.100015","url":null,"abstract":"<div><p>Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is characterized by bladder pain and lower urinary tract symptoms without obvious causes. A subset of patients with IC/BPS present with Hunner lesions (HL), which are focal regions of gross inflammation on the bladder wall. It has been previously proposed that cell populations within HL are enriched in B- and T-cells, suggesting that this form of IC/BPS may be caused by reaction to a specific antigen within the lesions. Alternatively, B-cell enrichment in the HL might be caused by generalized inflammatory processes. Here, we distinguished between these hypotheses by using single-cell sequencing to identify B-cell clonotypes in the HL and the bladder of IC/BPS patients. We identified a clonotype that is shared in two patients with IC/BPS and that represented a significant subpopulation of total immune cells within the lesions. This finding is strong evidence that B-cells in the patients’ bladders are reacting to a specific antigen. Further studies of this specific B-cell clonotype can identify the antigen, helping to define the pathophysiology for IC/BPS with HL.</p></div>","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"4 ","pages":"Article 100015"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772974522000096/pdfft?md5=513492df0925eca426eb11c34b0cf142&pid=1-s2.0-S2772974522000096-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73577393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Comment regarding: COVID-19- associated Guillain–Barrè Syndrome and Urinary Dysfunction: A case report","authors":"Peter F.W.M. Rosier","doi":"10.1016/j.contre.2022.100018","DOIUrl":"10.1016/j.contre.2022.100018","url":null,"abstract":"","PeriodicalId":100330,"journal":{"name":"Continence Reports","volume":"4 ","pages":"Article 100018"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772974522000126/pdfft?md5=a24bc899eb13db3bace7c82eb4fa85f2&pid=1-s2.0-S2772974522000126-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83931792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}